Novartis Plays Access Card As Kisqali Gets EU Approval
The Swiss major says that it 'eagerly awaits' a NICE decision on its advanced breast cancer treatment so patients in England and Wales get access quickly.
You may also be interested in...
Updated data from the MONALEESA-7 study shows the extent of its progression-free survival benefit in premenopausal women with advanced breast cancer; supplemental filings are planned.
Novartis has packaged and priced Kisqali – the second CDK4/6 inhibitor approved in the US – to compete with Pfizer's Ibrance, which made the mechanism of action the standard of care in untreated metastatic HR+/HER2- breast cancer.
BenevolentAI has added Merck KGaA to its list of partners but the UK firm is looking for a new CEO after Joanna Shields decided to leave as a major restructuring continues.